SINGAPORE – March 25, 2015 – Quintiles Head of Asia Markets Anand Tharmaratnam, M.D., last night was honored as “Best Life Science Asian Male Executive of the Year” at the BioPharma Asia Industry Awards. Dr. Tharmaratnam was selected in a vote of biopharmaceutical industry professionals from five distinguished executives shortlisted for the award.
“On behalf of the hundreds of voters who made their voices heard in the competition, we are pleased to present this award to Dr. Tharmaratnam,” said Sharon Roessen, Managing Director of Terrapinn Pte Ltd, organizer of BioPharma Asia Convention 2015. “His visionary leadership and Quintiles’ stellar work were frequent themes in voter comments. We would like to thank Anand for his contributions to advancing Asia’s biopharma industry.”
Over the past 11 years, Dr. Tharmaratnam has led Quintiles’ expansion in size and service offerings across the region. Quintiles now has more than 10,000 employees in 13 Asia-Pacific countries with half the world’s population – including China and Japan, respectively the world’s second- and third-largest biopharma markets. In 2014, Quintiles Asia-Pacific’s service revenues were $858 million USD.
“I am honored and humbled to have won this award,” Dr. Tharmaratnam said at last night’s awards dinner in Singapore. “I’d like to dedicate this award to my fellow Quintiles colleagues and to our customers who entrust us with advancing their investigational therapies to save lives and relieve suffering. Together we are creating a healthier world.”
Quintiles has won BioPharma Asia’s “Best CRO in Asia” award three times in the event’s five-year history, and last year – for the sixth time in eight years – was named Asia-Pacific CRO of the Year by Frost & Sullivan, a leading business research and consulting firm.
At this week’s BioPharma Asia Convention, Quintiles’ experts Dr. Karen Wai and Edwin Sia led roundtables on “Pan-Asian clinical trials coordination” and “Improving clinical supply importation and exportation,” respectively, and Wendy Bilham, Quintiles’ Head of Therapeutic Science and Strategy, Asia-Pacific, presented a case study on “Improving your probability of success in clinical trials in Asia.”
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s largest provider of biopharmaceutical development and commercial outsourcing services. With a network of more than 32,000 employees conducting business in approximately 100 countries, we helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Contact: Jay Johnson, Media Relations (email@example.com)
+65.6602.1297 (office) +65.9655.6635 (mobile)
Karl Deonanan, Investor Relations (InvestorRelations@quintiles.com)